Park Dental Partners, Inc. Common Stock (PARK)
🔔 Watch stock
symbol.quality_heading
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
The foundation holds (net cash, positive cash flow, genuine patient business), yet too much is still open to speak of a proven winner: a thin and recently shrinking margin, extreme concentration on Minnesota and on a single owner, the structural risk of the administrative agreements, and a trading history of less than twelve months. We see no acute danger, but no solid basis yet for treating the fresh micro cap as a sure thing — the decision is yours.
symbol.quality_note
Park Dental Partners (Nasdaq: PARK) takes the paperwork off dentists' hands and collects practices along the way — a business running since 1972 that only reached the stock market in December 2025, at $13.00 a share. We read the first annual report (10-K) and the IPO prospectus: $244 million in revenue, but earnings that flipped into a loss in 2025, almost every practice inside a single state, and a company that legally does not own its own dental offices. Not investment advice — just a sober look at a micro cap whose oldest asset is its business and whose youngest is its share price.
Read the analysis
Stock Watch
This analysis is as of July 27, 2026. Stock Watch will tell you what's changed at PARK since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
ThreatenedDer 10-K widmet künstlicher Intelligenz in Item 1A einen eigenen Risikofaktor: KI und verwandte Technologien werden im Dentalmarkt zunehmend eingesetzt (Bildgebungs-Diagnostik, Behandlungsplanung, Patientenkommunikation, Verwaltungsautomatisierung), die FDA lässt vermehrt KI-gestützte Dentalgeräte zu, und Wettbewerber integrieren diese Technologien in ihre Angebote. Der Bericht nennt das ausdrücklich als konkretes Wettbewerbsrisiko fürs eigene Modell — ein Versäumnis bei Bewertung und Einführung könne Park Dental ins Hintertreffen bringen und die Fähigkeit beeinträchtigen, Patienten und Fachkräfte zu gewinnen. KI ist bei Park Dental keine eigene Umsatzquelle und kein belegtes operatives Werkzeug; damit greift Kategorie »Bedroht« vor »Neutral«.
View the full file — quotes, sources, reviewed filings
„Artificial intelligence and related technologies are being increasingly adopted across the dental industry for applications including diagnostic imaging analysis, treatment planning assistance, patient communication, and administrative automation. The U.S. Food and Drug Administration (FDA) has cleared a growing number of AI-enabled dental devices, and competitors are incorporating these technologies into their service offerings. Failure to effectively evaluate, adopt, and integrate appropriate AI and other emerging technologies could place us at a competitive disadvantage and impair our ability to attract patients and dental professionals."
Künstliche Intelligenz und verwandte Technologien werden in der Dentalbranche zunehmend eingesetzt — unter anderem für die Analyse bildgebender Diagnostik, die Unterstützung der Behandlungsplanung, die Patientenkommunikation und die Verwaltungsautomatisierung. Die US-Arzneimittelbehörde FDA hat eine wachsende Zahl KI-gestützter Dentalgeräte zugelassen, und Wettbewerber integrieren diese Technologien in ihre Angebote. Versäumten wir es, geeignete KI und andere neue Technologien wirksam zu bewerten, einzuführen und zu integrieren, könnte uns das ins Wettbewerbsnachteil bringen und unsere Fähigkeit beeinträchtigen, Patienten und Zahnfachkräfte zu gewinnen.
„The increasing use of artificial intelligence and emerging technologies in dental care creates both competitive pressures and regulatory uncertainties that could affect our business. [...] Conversely, if we do not adopt AI technologies that become standard in the industry, we may lose competitive position."
Die zunehmende Nutzung künstlicher Intelligenz und neuer Technologien in der Zahnmedizin erzeugt sowohl Wettbewerbsdruck als auch regulatorische Unsicherheiten, die unser Geschäft beeinträchtigen könnten. [...] Umgekehrt könnten wir an Wettbewerbsposition verlieren, wenn wir KI-Technologien nicht übernehmen, die zum Branchenstandard werden.
Filings Reviewed: 10-Q 2026-05-14 · 10-K 2026-03-25 · 424B4 2025-12-03
Rated on July 10, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.05 | – | 57 | – | -0.40 | 4 | 2 |
| 2025: Q1 | 0.46 | -5.70 | 61 | 3.80 | 3.40 | 6 | 3 |
| 2025: Q2 | 0.46 | -5.70 | 61 | 3.80 | 3.40 | 5 | 3 |
| 2025: Q3 | 0.28 | 468.60 | 61 | 10.70 | 2.00 | 8 | 6 |
| 2025: Q4 | -1.27 | – | 61 | 7.50 | -9.40 | 1 | -1 |
| 2026: Q1 | -0.09 | -118.90 | 63 | 2.70 | -0.60 | 5,026 | 2,721 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Assessment: Opportunities & Risks
A real business running since 1972: 86 practice locations, $244.5 million of revenue (up 6.4 percent), 5.8 percent growth per existing practice, 89.9 percent patient retention, a leading market position in Minnesota. A DSO roll-up with genuine, recurring patient business — not a story stock.
Conservatively financed: $25.2 million in cash against just $9.8 million of bank debt (net cash), positive operating cash flow of $17.6 million, equity positive again after the IPO. Unlike many debt-financed roll-ups there is no mountain of debt here — the leverage one might expect in this business model is deliberately absent.
GAAP earnings flipped into a small loss in 2025 (minus $0.4 million, after plus $4.4 million), and the first quarter of 2026 was negative too. Many of the costs are one-off IPO items ($8.8 million of stock compensation), yet the adjusted margin is only around 9 percent and has been falling, because wages (up 10.3 percent) rise faster than revenue.
211 of 214 dentists in Minnesota, and a single owner (Dr. Alan Law) holds the specialty practices behind roughly 27 percent of revenue. On top of that comes the structural risk of the corporate practice of dentistry rules: Park Dental does not own the practices but consolidates them through administrative agreements whose legality, per the annual report, "may be challenged".
Optically cheap (price-to-sales ratio around 0.4), but that reflects the thin margin, not a bargain. The trading history is not yet twelve months old, the free float is tiny, the 180-day lock-up expired in early June 2026, and the stock has already roughly doubled from the $13 IPO. Analyst coverage is extremely thin.
Park Dental Partners is a solid but still unproven newcomer to the stock market: a dental practice management business (DSO) running since 1972, with $244.5 million of revenue, a clean net-cash balance sheet and a likeable, dentist-dominated ownership model — but with a thin and recently falling margin, extreme concentration on a single state and a single owner of the specialty practices, a legal structural risk (the company does not own its practices at all) and a stock that has already doubled from the $13 IPO. Statistically cheap, but not proven. Not investment advice.
- Materiality gate (as of July 10, 2026): the negative findings were quantified and typed. (1) Structural risk from the corporate practice of dentistry rules: in the extreme case it touches 100 percent of consolidated revenue, but it is an industry-standard, decades-old model explicitly regulated in Minnesota — a chronic structural finding, not an acute threat to existence. (2) Concentration: 211 of 214 dentists in Minnesota (virtually the entire operation) plus one owner with 27 percent of revenue — a material structural/cluster finding. (3) Earning power: a GAAP loss in 2025 (minus $0.4 million) and in the first quarter of 2026 (minus $0.4 million), an adjusted EBITDA margin of only about 9 percent and falling — a quality/earnings finding, largely amplified by one-off IPO costs but with genuine margin pressure from wages. No existential finding: the balance sheet is net-cash positive, operating cash flow is positive, debt is low — the debt-financed roll-up one might have suspected is explicitly NOT what this is. Result: no substance finding (no acute danger, solid balance sheet), but given the cluster of structural findings and the missing stock market history, quality is not proven but open, which is the "open questions" rating. The rating says nothing about the entry price — that is what the metric scanners are for.
- Valuation metrics are orders of magnitude as of mid-2026 (market value roughly $90–95 million, price/sales about 0.4, enterprise value/sales about 0.5); annual figures refer to fiscal year 2025 (as of December 31, 2025), quarterly figures to the first quarter of 2026 (as of March 31, 2026). Analyses are evergreen, daily prices are not a buy argument; the reference to the doubling relates to the IPO offering price of $13.00.
- Special situation: the 180-day lock-up for pre-IPO holders expired 180 days after the IPO closing of December 4, 2025 (early June 2026); several insider filings (Form 4) followed in June 2026. Eleven dentist shareholders (176,852 shares) extended their lock-up by 185 days in January 2026 in exchange for short-term promissory notes from the company to cover tax liabilities from IPO vesting. Roughly 698,056 affiliate shares remain subject to Rule 144 restrictions.
- AI rating: "threatened" (assessed July 10, 2026). Item 1A of the 10-K carries a dedicated risk factor stating that the growing spread of artificial intelligence in the dental market creates competitive pressure and regulatory uncertainty; competitors are integrating AI, the FDA is clearing more AI dental devices, and a failure to adopt could leave Park Dental behind. AI is not a revenue source for the company. Supporting quotes are in the AI dossier.
About the Company
Park Dental Partners, Inc. ist eine zahnmedizinische Ressourcenorganisation, die administrative Geschäftsunterstützungsdienste für Zahnärzte in Minnesota, Wisconsin und Arizona anbietet.
| Employees | 1,212 |
|---|---|
| Headquarters | Roseville, MN |
| Website | parkdentalpartners.com |
| IPO Date | 3. Dec 2025 |
| Next Earnings | 12. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Peter G. Swenson | President, CEO & Chairman of the Board | 1972 |
| Christopher James Bernander | CFO & Treasurer | 1983 |
| Alan Siems Law D.D.S., Ph.D. | Chief Clinical Officer of Specialty Practices & Director | 1966 |
| Christopher Eugene Steele D.D.S. | Chief Clinical Officer of General Practices & Director | 1964 |
| Brian Zard | Vice President of Operations | – |
| Jean Lind | Chief Administrative Officer & Secretary | – |
| Brian Delgado | Senior Director of Marketing | – |
| David Johnson CPA | Controller | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.